Form 8-K Filing by Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. has filed a Form 8-K detailing retention agreements with key executives, Christopher Gerry (President and Principal Executive Officer) and Josiah Craver (Senior Vice President of Finance and Principal Finance and Accounting Officer). Effective November 14, 2025, their annual base salaries are set at $425,000 and $400,000, respectively. Both are eligible for an annual target bonus of 40% of their base salaries starting in the year ending December 31, 2026. The agreements also include provisions for retention bonuses. A first retention bonus, equal to their full 2025 target annual bonus, is payable if they remain employed through February 13, 2026, or if their employment is terminated without cause or they resign for good reason prior to that date (not in connection with a change in control). A second retention bonus, pro-rated for 2026, is payable under similar termination conditions. If termination occurs without cause or resignation for good reason not connected to a change in control, the second retention bonus is doubled. These severance benefits are contingent upon the executives signing a separation agreement and release of claims. The filing was made on December 23, 2025.